Table 2.
Type of response | Patients, n | Entire cohort, % | Response evaluable, % |
---|---|---|---|
CR | 1 | 2.6% | 2.8% |
PR | 6 | 15.7% | 16.6% |
SD > 6 months | 5 | 13.2% | 13.9% |
ORR (CR + PR) | 7 | 18.4% | 19.4% |
Cytostatic ORR (CR + PR + SD ≥ 6 mo) | 12 | 31.6% | 33.3% |
Type of response | Patients, n | Entire cohort, % | Response evaluable, % |
---|---|---|---|
CR | 1 | 2.6% | 2.8% |
PR | 6 | 15.7% | 16.6% |
SD > 6 months | 5 | 13.2% | 13.9% |
ORR (CR + PR) | 7 | 18.4% | 19.4% |
Cytostatic ORR (CR + PR + SD ≥ 6 mo) | 12 | 31.6% | 33.3% |